Journal of Affective Disorders
Volume 105, Issue 1 , Pages 45-52 , January 2008

Weight change in the acute treatment of bipolar I disorder: A naturalistic observational study of psychiatric inpatients

Received 24 February 2007 ,Revised 5 April 2007 ,Accepted 5 April 2007.

References 

  1. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry. 2001;62(Suppl 7):22–31
  2. Barsh GS, Farooqi IS, O'Rahilly S. Genetics of body-weight regulation. Nature. 2000;404:644–651
  3. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am. J. Psychiatry. 1999;156:1417–1420
  4. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord. 2003;5(Suppl 2):62–79
  5. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 1995;122:481–486
  6. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J. Clin. Psychiatry. 2000;61:179–184
  7. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J. Clin. Psychiatry. 2001;62:486–491quiz 492–483
  8. Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J. Clin. Psychiatry. 2002;63:528–533
  9. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am. J. Psychiatry. 2003;160:112–117
  10. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7:424–430
  11. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J. Clin. Psychiatry. 2000;61:9–15
  12. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry. 2000;61:638–642
  13. Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ. Weight gain during treatment of bipolar I patients with olanzapine. J. Clin. Psychiatry. 2004;65:1679–1687
  14. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev. Nutr. Diet. 2005;94:1–12
  15. Kawachi I. Physical and psychological consequences of weight gain. J. Clin. Psychiatry. 1999;60(Suppl 21):5–9
  16. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J. Clin. Psychiatry. 2003;64:1426–1435
  17. Korean Ministry of Health and Welfare . In: The Korean National Health and Nutrition Survey 2001. 2002;p. 178–180
  18. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr. Psychiatry. 1980;21:270–275
  19. Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston JP, Ahl J, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J. Clin. Psychopharmacol. 2006;26:316–320
  20. Lissner L, Odell PM, D'Agostino RB, Stokes 3rd J, Kreger BE, Belanger AJ, et al. Variability of body weight and health outcomes in the Framingham population. N. Engl. J. Med. 1991;324:1839–1844
  21. McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Leverich GS, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J. Clin. Psychiatry. 2002;63:207–213
  22. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79
  23. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J. Affect. Disord. 2002;70:19–26
  24. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am. J. Epidemiol. 1995;141:1117–1127
  25. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159–171
  26. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr. Bull. 1995;21:463–472
  27. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabilizer alone. Br. J. Psychiatry. 2004;184:337–345
  28. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, et al. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range.. JAMA. 1995;273:461–465
  29. Wyatt SB, Winters KP, Dubbert PM. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am. J. Med. Sci. 2006;331:166–174

PII: S0165-0327(07)00129-2

doi: 10.1016/j.jad.2007.04.006

Journal of Affective Disorders
Volume 105, Issue 1 , Pages 45-52 , January 2008

Article Tools